Weather AlertMass General Brigham's hospital campuses and off-site facilities are fully open and operational as of Wednesday, Feb. 25, with the exception of some limited closures and delays. For real-time updates and service changes, please check our Alerts page.View Alerts page
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination with other Anticancer Agents in Participants with Advanced Solid Tumors
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
A Phase 1/2 Trial of TER-2013 in Participants with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
A Phase 2 Study of Abemaciclib in Combination with Letrozole or in Combination with Letrozole and Metformin in Recurrent or Persistent Endometrial Cancer
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors
A PHASE II STUDY OF TAILORED ADJUVANT THERAPY IN POLE-MUTATED AND p53-WILDTYPE/NSMP EARLY STAGE ENDOMETRIAL CANCER (RAINBO BLUE & TAPER)